Sanofi has announced that it will be acquiring Vigil Neuroscience and its investigational Alzheimer’s disease (AD) drug for ...

Sanofi’s acquisition of Vigil Neuroscience involves purchasing the company for $8 per share in cash, along with an additional $2 in contingent value rights, pending the commercial success of ...

Paris: Sanofi has completed the acquisition of DR-0201, a targeted bispecific myeloid cell engager, from Dren Bio, Inc., a ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

Ivonescimab helped cut the risk of lung tumor progression in half in a multi-country Phase 3 trial. But it hasn’t yet clearly ...

May 22, 2025 Sanofi to acquire Vigil Neuroscience in $470 million deal to boost neurological pipeline Sanofi will acquire Vigil Neuroscience , a clinical-stage biotech company in a $470 million ...

Japan’s Nippon Steel is set to finalize its acquisition of U.S. Steel for $55 per share, following a green light from ...

In its most recent quarter, Nvidia delivered blockbuster results, driven by full-scale production of its Blackwell GPUs and ...

The latest price target for Vigil Neuroscience (NASDAQ:VIGL) was reported by JMP Securities on May 22, 2025. The analyst firm set a price target for $0.00 expecting VIGL to fall to within 12 ...

Eli Lilly has reached a deal to acquire SiteOne Therapeutics that would give it control of a non-opioid pain drug that would ...